The applicant has subsequently filed a sequence listing and declared, that it includes no new matter.

(71) Applicant: **AMERICAN CYANAMID COMPANY**
One Cyanamid Plaza
Wayne
New Jersey 07470 (US)

(72) Inventor: **Lai, Margaret Hsien-Fen Kuh**
18 Manton Avenue
East Brunswick,
New Jersey 08816 (US)
Inventor: **Kirsch, Donald Richard**
152 Terhune Road
Princeton,
New Jersey 07066 (US)
Inventor: **Bard, Martin**
872 Joann Court
Carmel,
Indiana 46032 (US)

(74) Representative: **Wächtershäuser, Günter, Prof. Dr.**
Patentanwalt
Tal 29
D-80331 München (DE)

(54) **Sterol delta-14 reductase screen.**

(57) A binary assay identifies agents that inhibit sterol $\Delta 14$ reductase involved in ergosterol biosynthesis. In the primary screen, sterol $\Delta 14$ reductase inhibition by a test sample is assayed by adding the test sample to a culture of *Neurospora crassa* having an erg-3 mutation and also to a culture of a strain having an erg-1 mutation, comparing the extent of growth inhibition after incubation in the two cultures, and identifying as positives those samples that show growth inhibition in the erg-3 culture exceeding that in the erg-1 culture. In the secondary screen, samples that test positive in the primary screen are reassayed by adding the test sample to a culture of a *Saccharomyces cerevisiae* strain into which has been introduced multiple copies of a gene encoding sterol $\Delta 14$ reductase and also to a strain of *S. cerevisiae* that does not have the introduced gene; positive samples are identified after incubation by observation that growth inhibition in the culture having no introduced reductase gene exceeds growth inhibition in the culture having the introduced reductase gene. In preferred embodiments, a known inhibitor of sterol $\Delta 14$ reductase is employed in solidified media in both the primary and the secondary screens, resulting in an assay that is highly sensitive and specific for the detection of sterol $\Delta 14$ reductase inhibitors.

EP 0 644 268 A2

Technical Field of the Invention

This invention relates to a screening method for the identification of agents that inhibit the sterol Δ14 reductase enzyme of sterol biosynthesis.

5

Background of the Invention

Sterols are Steroid alcohols of vegetable and animal origin. Ergosterol is the principal membrane sterol of fungi. It is structurally similar to its animal counterpart, cholesterol, and its higher plant counterparts, stigmasterol and sitosterol. Though the biosynthesis of ergosterol in fungi involves steps distinct from the other sterols, the pathways in different organisms share several common steps. The lanosterol 14α-demethylation steps in cholesterol and ergosterol formation in animals and fungi, as well as the obtusifoliol 14α-demethylation in stigmasterol and sitosterol biosynthesis in plants, both lead to the formation of a double bond between carbons 14 and 15 of the sterol ring. This double bond is then reduced by sterol Δ14 reductase activity. The enzyme is located in the microsomal fraction in pig liver, yeast and *Zea mays*, and requires NADPH as an electron donor (Marcireau, C., *et al., Curr. Genet. 22*: 267-272 (1992)).

Genetic studies of ergosterol biosynthesis mainly have been carried out in *Saccharomyces cerevisiae* (Paltauf, F., *et al.*, in Jones E.W., *et al.*, eds., *The Molecular and Cellular Biology of the Yeast Saccharomyces, Gene Expression*, Cold Spring Harbor Laboratory Press, 1992, pages 434-437). In yeast, ergosterol affects membrane fluidity and permeability and plays an essential role in the yeast cell cycle. Mutations in the biosynthetic pathway are generally recovered by selecting for resistance to polyene antibiotics. Polyenes bind to ergosterol in the plasma membrane and produce pores through which ions can flow leading to cell death. Mutants with lower levels of plasma membrane ergosterol bind less polyene and show increased resistance. This method has permitted the recovery of mutations in many of the genes in the pathway.

A series of polyene-resistant mutants of *Neurospora crassa* were isolated several years ago, although little work was done at that time to characterize the mutations on a molecular level. Recently, Grindle and co-workers characterized one of these *Neurospora crassa* mutants, denoted erg-3, and found that it carried a genetic lesion in sterol Δ14 reductase activity (Ellis, S.W., *et al., J Gen. Micro. 137*: 267-272 (1992)). The sterol Δ14 reductase gene in *S. cerevisiae*, denoted ERG24, also has recently been cloned and sequenced (Lorenz, T., and Parks, L.W., *DNA and Cell Biol. 11*: 685-692 (1992)).

Toward the end of the biosynthetic pathway of ergosterol biosynthesis, sterol Δ14 reductase and Δ8 - Δ7 isomerase catalyze steps in the conversion of lanosterol to ergosterol. After ignosterol is reduced by sterol Δ14 reductase, the sterol is demethylated and rearranged to fecosterol, which is then isomerized by sterol Δ8 - Δ7 isomerase. Mechanism of action studies indicate that several morpholine and structurally related piperidine compounds having large ring N-substituents such as dodemorph, tridemorph, aldimorph, fenpropimorph, amorolfine, and fenpropidin, currently marketed as fungicides, act via the inhibition of these two enzymes (Mercer, E.I., *Bio-chem. Soc. Trans. 19*: 788-308 (1991)). This conclusion stems in part from the observation that substrates for the enzymes build up in fungal cells treated with low levels of the fungicides. However, it recently has been found that the sterol Δ8 - Δ7 isomerase gene is not essential for viability in *S. cerevisiae* (Ashman, W.H., *et al., Lipids 26*: 628-632 (1991)), suggesting that the killing effect of morpholine fungicides may be primarily the result of sterol Δ14 inhibition.

Summary of the Invention

45

It is an object of the invention to provide a screening test for the identification of agents exhibiting sterol biosynthesis inhibition.

It is another object of the invention to provide a screening test to identify agents exhibiting potential fungicidal activity for a wide variety of agricultural, medical, and veterinary uses.

It is a further and more specific object of this invention to identify agents that inhibit the sterol Δ14 reductase reaction in the ergosterol biosynthetic pathway.

These and other objects are accomplished by the present invention, which provides a method for the identification of agents which inhibit sterol Δ14 reductase involved in ergosterol biosynthesis. The method is a screening test that, in the most preferred embodiment, involves a primary and a secondary screen. In the primary screen, sterol Δ14 reductase inhibition by a test sample is assayed by adding the test sample both to a culture of a *Neurospora crassa* strain having an erg-3 mutation (such as FGSC2725) and to a culture of a *Neurospora crassa* strain having an erg-1 mutation (such as FGSC2721). The samples are incubated for such time under such conditions sufficient to observe fungal cell growth in corresponding cultures

2

containing no test sample, and the extent of growth inhibition in the two cultures is compared. Sterol Δ14 reductase inhibition is determined by observing that growth inhibition in the erg-3 culture containing the test sample exceeds growth inhibition in the erg-1 culture containing the test sample In preferred embodiments, a known inhibitor of sterol biosynthesis such as tridemorph or fenpropimorph is added to solidified cultures as a control, and test and control samples are added on a disk or in a well so that inhibition can be easily observed visually.

In the secondary screen, samples that test positive in the primary screen are reassayed by adding the test sample to a culture of a *Saccharomyces cerevisiae* strain into which has been introduced multiple copies of a gene encoding sterol Δ14 reductase such as strain Y294(pML100), and also to a culture of a corresponding *Saccharomyces cerevisiae* strain which does not have an introduced sterol Δ14 reductase gene such as Y294(YEp13). The samples are incubated in the cultures for such time under such conditions sufficient to observe yeast cell growth in corresponding cultures containing no test sample, and the extent of growth inhibition is compared. The presence of sterol Δ14 inhibition is determined by observation that growth inhibition in the culture having no introduced reductase gene exceeds growth inhibition in the corresponding culture having the introduced reductase gene. In preferred embodiments, a known inhibitor of sterol Δ14 reductase, such as fenpropimorph, is added to solidified cultures as a control, and test and control samples are added on a disk or in a well so that inhibition can be easily observed visually.

Each screen can be employed independently to assay for sterol Δ14 reductase inhibition. However, the *N. crassa* screen is less specific than the *S. cerevisiae* screen, and the *S. cerevisiae* screen is less sensitive than the *N. crassa* screen. Therefore, preferred embodiments employ both screens. When carried out together, the binary assay comprising the two screens is highly sensitive and specific for the detection of sterol Δ14 reductase inhibitors.

Brief Description of the Figures

Figure 1 shows restriction maps of four plasmid inserts recovered via selection for fenpropimorph resistance in *Saccharomyces cerevisiae* as described in Example 2. Selected restriction enzyme digestion sites are shown for each insert.

Figure 2 shows fenpropimorph resistance of subclones of pML100, a plasmid containing the cloned sterol Δ14 reductase gene.

Detailed Description of the Invention

This invention is based upon the finding that a pair of *Neurospora crassa* mutants defective in ergosterol bio-synthesis enzymes are useful in a sensitive and reasonably specific assay for sterol, Δ14 reductase inhibition. A second, less sensitive screen employing a *Saccharomyces cerevisiae* strain into which has been introduced a gene encoding sterol Δ14 reductase at high copy is also useful and reasonably specific for sterol Δ14 reductase inhibitors. When carried out together, the screens are highly sensitive and specific for the detection of sterol Δ14 reductase inhibitors.

Two *Neurospora crassa* mutants defective in ergosterol biosynthesis are employed in screening according to the method of the invention. One is an erg-1 mutant defective in sterol Δ8 - Δ7 isomerase and the other is an erg-3 mutant defective in sterol Δ14 reductase. Any *N. crassa* erg-1 or erg-3 mutants may be used, such as, for example, those prepared by Grindle, *et al.*, by ultraviolet mutagenesis of wild-type *Neurospora* (Ellis, E.W., *et al.*, cited above, and Grindle, M., and Farrow, R., *Mol. Gen. Genet. 165*: 305-308 (1978)). Strains may also be obtained from the Fungal Genetics Stock Center (FGSC). In one embodiment, erg-1 mutant FGSC2721 and erg-3 mutant FGSC2725 are employed.

Erg-3 mutants are much more sensitive to morpholine-type fungicides (morpholines and structurally related piperidines) than the wild-type parent strain. For example, in morpholine sensitivity comparisons in cultured plates, the following differences in the size of zone inhibition are obtained in the lawns of the cultures:

3

Strain	Description	Size of Inhibition Zone		
		Tridemorph	Fenpropimorph	Fenpropidin
2490	wild-type	27.5 mm	28.0 mm	24.5 mm
2721	erg-1	28.5 mm	30.5 mm	33.0 mm
2725	erg-3	38.5 mm	38.0 mm	37.0 mm

However, the erg-3 mutant strain also shows increased sensitivity to a large number of compounds with varied mechanisms of action, perhaps due to general increased plasma membrane permeability exhibited by the strain. To control for this effect, the erg-1 mutant strain, which, as illustrated in the above data, shows a fairly normal level of sensitivity to morpholine-type fungicides relative to the wildtype and is more sensitive to other compounds, is used as a control in the screen.

In the practice of the screening method for the presence or absence of sterol biosynthesis inhibition by a test sample using the method of the invention, the test sample is added to a culture of a *Neurospora crassa* strain having an erg-3 mutation and also to a second culture of a *Neurospora crassa* strain having an erg-1 mutation. The samples are incubated in the cultures for such time under such conditions sufficient to observe fungal cell growth in corresponding cultures containing no test sample. In preferred embodiments, sterol Δ14 reductase inhibitors are added to both cultures as controls. The extent of growth inhibition in the culture containing the erg-3 mutation is then compared with the extent of growth inhibition in the culture containing the erg-1 mutant. The presence of sterol biosynthesis inhibition, particularly sterol Δ14 reductase inhibition, is determined by observation that growth inhibition in the erg-3 culture exceeds growth inhibition in the erg-1 culture.

Any type of solidified or livid media that will support growth and reproduction of the *N. crassa* strains may be employed as cultures in the method of this invention. Numerous media are known to the skilled artisan, and an advantage of the invention is that the ascomycete fungus has been studied rather extensively and grown in a variety of conditions. Conidia suspensions can be stored for weeks. Example media include Difco Neurospora Minimal Media, Vogel's Media containing salts, sucrose and biotin, and yeast media containing yeast extract and sorbose. Example media are provided hereinafter.

Where liquid cultures are employed, differences in growth are generally determined by observing and comparing turbidity; for this purpose, optical density (OD) readings at 550 to 650 nm are made and compared. Preferred media, however, are solidified by adding agar or gelatin forming cultures in plates or dishes. Agar is especially preferred.

In preferred embodiments, a positive control is employed to assist in the identification of potential agents. In these embodiments, a known inhibitor of sterol biosynthesis is employed. For example, a known sterol Δ14 reductase inhibitor such as tridemorph, fenpropimorph, or fenpropidin is useful as a control. Positive controls are added to cultures or culture areas of both *N. crassa* strains, and the control effects on culture growth are compared to the cultures or culture areas with the test samples. Tridemorph is preferred in one embodiment; in solidified cultures, a 200 ng tridemorph disk gives a clear differential response.

As mentioned above, particularly preferred embodiments employ solidified media, so that test samples and positive controls are observed visually and simultaneously as regions of the same culture. Samples or controls are introduced on a disk or in a well of the plate. Inhibition is observed visually as measurable zones around disks or wells in the lawn of growth in the plate or dish. Actives produce a larger zone around test samples grown in a lawn of the erg-3 strain than in a lawn of the erg-1 strain.

A distinct advantage of this screening method is its speed and simplicity. The protocol is simple. Many samples are readily analyzed in a short time, providing new potential sterol biosynthesis inhibitors, notably sterol Δ14 reductase inhibitors. The inhibitors can be employed in the arsenal against undesirable fungi, some of which are resistant to currently known fungicides, and interfere with pathogen but not host metabolism.

It is another advantage of this screening method that it is sensitive, and only small amounts of biochemical or chemical agents are required for the test. In a standard assay, for example, which employs solidified media in a plate, as little as 10 ng fenpropimorph or fenpropidin, and 20 ng of tridemorph are detected.

As revealed in screens of over 7000 compounds set out in Example 1 below, the assay is not completely selective, however, and a few compounds that are not inhibitors of ergosterol biosynthesis test positive. Therefore, preferred embodiments employ the assay only as a primary screen. Compounds testing positive in the screen are then reassayed with a *Saccharomyces cerevisiae* ergosterol Δ14 reductase

4

assay as a secondary screen.

In the *Saccharomyces cerevisiae* screening method for the presence or absence of sterol Δ14 reductase inhibition by a test sample, the test sample is added to a culture of a *S. cerevisiae* strain into which has been introduced a gene encoding sterol Δ14 reductase, preferably at high copy. The test sample is also added to a culture of a corresponding *S. cerevisiae* strain which does not have an introduced sterol Δ14 reductase gene. The samples are incubated in the cultures for such time under such conditions sufficient to observe yeast cell growth in corresponding cultures containing no test sample, and the extent of growth inhibition in the culture having the reductase gene is compared with the extent of growth inhibition in the culture having no introduced gene. The presence of sterol Δ14 reductase inhibition is determined by observation that growth inhibition in the culture having no introduced reductase gene exceeds growth inhibition in the culture having the introduced reductase gene.

Any *S. cerevisiae* strain into which has been introduced a gene encoding sterol Δ14 reductase can be employed in the screen. Typical strains are obtained by cloning the sterol Δ14 reductase gene and integrating it at multiple sites into the chromosome of wild-type or parental strains, or by transforming a wild-type or parental strain with a multi-copy plasmid encoding the enzyme. The gene has been cloned by selecting strains resistant to fenpropimorph and fenpropidin as set out in Example 2 below and in Lorenz, T., and Parks, L.W., *DNA and Cell Biol. 11*: 685-692 (1992) and in Marcireau, *et al.*, cited above. Sterol analysis of mutants carrying the disrupted gene demonstrate the accumulation of the sterol Δ14 reductase substrate, ignosterol. Cloned genes have been sequenced (ID SEQ No. 1 set out hereinafter) and found to be substantially identical (Lorenz and Parks, cited above, and Example 2 below), encoding a 438 amino acid, 50.5 kilo-dalton, basic (pl = 9.2) protein. Preferred strains are morpholine resistant when the gene is introduced at high copy.

In the practice of the invention, growth inhibition by a test sample in the yeast strain having an introduced sterol Δ14 reductase gene, such as strain Y294 transformed with a plasmid encoding the gene, such as pML99, pML00, pML101 or pML103, particularly pML100, (described in detail hereinafter), is compared to another strain such as a corresponding wild-type or parental strain having no introduced gene. A parental strain exhibiting similar growth characteristics but having no introduced gene is preferred for the comparison. Where strain Y294(pML100) is employed as the strain having the reductase gene, for example, another Y294 strain is used in the screen, most preferably a strain transformed with a similar plasmid that does not encode the gene. An example illustrated below employs Y294(YEp13) in screens with Y294-(pML100).

Any type of solidified or liquid media that will support growth and reproduction of the *S. cerevisiae* strains may be employed as cultures in the method. Numerous yeast media are known to the skilled artisan, and an advantage of the invention is that baker's yeast is relatively easy to grow. Typical media are yeast extract, peptone and dextrose (YEPD) or yeast extract and dextrose (YED) media; yeast basal growth media (YBGM) containing glucose, vitamins, minerals, and water; yeast extract, peptone, and adenine sulfate (YPA) media; yeast mannitol (YM) media and YM plus glucose; synthetic dextrose (SD) media containing dextrose, a nitrogen base, water, and, optionally amino acids, adenine sulfate and uracil; and the like. Example media are provided hereinafter.

Where liquid cultures are employed, differences in growth are generally determined by observing and comparing turbidity; for this purpose, optical density (OD) readings at 550 to 650 nm are made and compared. Preferred media, however, are solidified by adding agar or gelatin to form cultures in plates or dishes. Agar is especially preferred. In these embodiments, differential growth between the strains is observed visually and simultaneously as regions of the same culture. Samples are introduced on a disk or in a well of the plate. Inhibition around the disk or well in the lawn of growth of the strain having the gene is compared to inhibition around the disk or well in the lawn of the strain that does not have the introduced gene. Actives produce a smaller zone on the strain with the gene than in the other strain.

In preferred embodiments, a positive control is employed to assist in the identification of potential agents. In these embodiments, a known inhibitor of sterol Δ14 reductase is employed, such as, for example, fenpropimorph, fenpropidin, tridimorph, or azasterol or a mixture of these. Fenpropimorph is preferred in one embodiment. Positive controls are added to cultures or culture areas of both *S. cerevisiae* strains, and the effects of the control on culture growth are compared to the cultures or culture areas with the test samples to assess activity of test samples on the two strains.

As previously noted, the secondary screen can, in some embodiments, be employed as a primary screen for sterol Δ14 reductase inhibitors. However, since *S. cerevisiae* is naturally less sensitive to morpholines than *N. crassa*, the assay is intrinsically less sensitive than the primary screen using *N. crassa* described above. Therefore, as set out above, the *S. cerevisiae* screen is preferably employed as a secondary screen to test positive samples from the *N. crassa* primary screen.

5

Morpholines are detected in the *S. cerevisiae* screen at about 12.5 μg/disk for fenpropimorph and fenpropidin and 50 μg/disk for tridimorph. As a result, in preferred embodiments, actives from-the *N. crassa* primary screen are concentrated about 2500-fold prior to testing in the secondary screen. As set out in Example 3 hereinafter, all of the actives from the primary screen with undesired mechanisms of action are inactive in the secondary assay. Hence, when carried out together, the two screens are highly sensitive and specific for the detection of sterol Δ14 reductase inhibitors.

The binary sterol Δ14 reductase assay exhibits a low positive rate assay if compounds which do not inhibit sterol Δ14 reductase in the primary screen are eliminated using the secondary screen. Other tests are, therefore, not of high importance. However, standard *in vitro* and *in vivo* fungicide discovery screens are employed in some embodiments as tertiary tests to prioritize actives from the binary assay.

The *in vitro* screens test samples for their ability to inhibit the growth of selected phytopathogenic fungi cultured in nutrient agar. Three of these species typically employed, *Pseudocercosporella her-potrichoides* causing wheat eyespot, *Rhizoctonia solani* causing rice sheath blight, and *Fusarium oxysporum* causing damping off, synthesize ergosterol. In practice, fenpropomorph and tridemorph are primarly active *in vitro* against *Rhizoctonia solani* in the 1 ppm range (1 μg/ml), while fenpropimorph is detected at ~10 ng/ml in the sterol Δ14 reductase primary screen if 30 μl volumes are tested in welled plates. Thus, fermentations in the *in vitro* screen are generally retested after about a 200-fold concentration.

In *in vivo* screens, a variety of phytopathogenic fungi are used to infect plants treated with test compounds. Active compounds block or reduce the appearance of disease symptoms. A number of model plant infections are employed in the screen and include fungi that cause apple scab (*Venturia inaequalis*), grape downy mildew (*Botrytis cinerea*), pepper botrytis (*Botrytis cinerea*), rice blast (*Pyricularia oryzae*), sugar beet cercospora (*Cercospora beticola*), tomato early blight (*Alternaria solani*), wheat leaf rust (*Puccinia recondita tritici*), and wheat powdery mildew (*Erysiphe graminis tritici*). The most potent test compounds in these assays are active in the 10 ppm range. When morpholines are specifically tested in this screen, fenpropimorph and tridemorph are active at about 10 ppm, mainly against the powdery mildews. These data indicate that extensive concentration (~2000 fold) are necessary to evaluate actives from this tertiary screen. All of the species in this test except one, *Plasmopara viticola*, grape downy mildew, synthesize ergosterol and are potential targets for ergosterol synthesis inhibitors.

The following examples are presented to further illustrate and explain the present invention and should not be taken as limiting in any regard. As used herein, fungal strains obtained from the Fungal Genetics Stock Center, University of Kansas Medical Center, Kansas 66103, USA are denoted "FGSC". Strains from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA, are denoted "ATCC". Fenpropimorph, fenpropidin and tridemorph are purchased from Crescent Chemical Company, Inc., Hauppauge, New York. Synthetic dextrose (SD) media contains 0.7% yeast nitrogen base without amino acids, 2% dextrose and 2% agar. Yeast extract, peptone and dextrose (YEPD) media contains 1% yeast extract, 2% peptone, 2% dextrose and 2% agar.

These examples employ both *Saccharomyces cerevisiae* and *Neurospora crassa*. To avoid confusion between the nomenclature of these two species, the gene correspondence of ergosterol biosynthetic pathway enzymes is as follows:

Enzyme	*S. cerevisiae* Gene	*N. crassa* Gene
Δ14 reductase	ERG24	erg-3
C-24 methyl transferase	ERG6	erg-4
Δ8-Δ7 isomerase	ERG2	erg-1
C-24(28) reductase	ERG4	erg-2

(see Paltauf, *et al.*, Grindle and Farrow, and Lorenz and Parks references cited above).

Example 1

This example describes a sterol Δ14 reductase primary screen using erg-1 and erg-3 *Neurospora crassa* strains.

Fungal strains FGSC2721 (erg-1) and FGSC2725 (erg-3) are cultured as follows. A suspension of conidia stored at 4°C in 0.005% Tween® 80 is stable for at least 6 weeks. Every 6 to 8 weeks, a fresh culture is prepared by coating the lower half of three 250 ml Erlenmeyer flasks with Neurospora minimal

media or Vogel's minimal media described below. This is most easily accomplished by adding 25 ml molten agar media with 12.5 units of nystatin for FGSC2725 and 25 ml molten agar media for FGSC2721 to each flask, then tilting the flask in an ice bath, and rolling it quickly until the agar hardens in an even coating. A few drops (~0.1-0.2 ml) of culture or conidial suspension are added to each flask, and spread around to evenly wet the agar surface by rolling the flask. The flasks are incubated for 2 to 3 days in the dark (e.g., foil wrapped) at room temperature or 37°C. When generous aerial growth is obtained, the unwrapped flasks are placed under a fluorescent lamp or placed by a window to induce sporulation. The orange conidia can be harvested after 5 or more days by rinsing the flasks twice with 5 ml 0.005% Tween® 80 and a small quantity of 0.3 mm glass beads. Yields should be ~30 ml, at $0.5 - 1.0 \times 10^8$ spores per ml (determined using a hemocytometer). Working stock solution for the screen should be adjusted to $\sim1 \times 10^7$ spores per ml 0.005% Tween® 80.

Neurospora minimal media is prepared by combining

Difco Neurospora Minimal Media	27.7 gm
Difco Agar	20.0 gm
Distilled Water	1000 ml

and autoclaving 15 minutes at 20 pounds pressure.

Vogel's minimal media is prepared as set out below. A trace minerals solution is first prepared for use as an ingredient in the stock salts solution, by adding in order, to 95 ml distilled water with continuous stirring:

Citric Acid • H_2O	5 g
$ZnSO_4 • 7H_2O$	5 g
$Fe(NH_4)_2(SO_4)_2 • 6H_2O$	1 g
$CuSO_4 • 5H_2O$	0.25 g
$MnSO_4 • H_2O$	0.05 g
H_3BO_3	0.05 g
$NaMoO_4 • 2H_2O$	0.05 g

The solution is stored at room temperature over 1 ml chloroform.

A liter of a 50X Stock Salts Solution is prepared by dissolving the following, in order, with continuous stirring, in 750 ml distilled water:

Sodium Citrate • 5 1/2 H_2O	150 g
KH_2PO_4	250 g
NH_4NO_3	100 g
$MgSO_4 • 7H_2O$	10 g
$CaCl_2 • 2H_2O$	5 g
Trace Minerals Solution	5 ml
Biotin (0.1 mg/ml)	2.5 ml

The pH of the solution is adjusted to ~5.8 and distilled water is added to a final volume of 1 liter. The solution is stored at room temperature over 2 ml chloroform.

To prepare Vogel's media, combine

Vogel's 50X Salts Solution	20 ml
Sucrose	15 gm
Agar	20 gm
and add	
Distilled Water to	1000 ml.

Autoclave 15 minutes at 20 pounds.

Media for the primary sterol Δ14 reductase screen is prepared by combining

Yeast Morphology Agar	35 gm
Yeast Extract	1 gm
L-Sorbose	25 gm
and adding	
Distilled Water to	1000 ml.

The innocula are the counted suspensions of FGSC2725 and FGSC2721 spores. Working stocks are 5 x 10^6 to 1 x 10^7 spores/ml as described above. One part spores is added to 100 parts media.

For the screen, plates are poured and dried before duplicate test samples are each added to a FGSC2725 plate and a FGSC2721 plate. Each test should include a positive control that gives a clear response such as a 200 ng tridemorph disk. The plates are incubated 48 hours at 37°C. Positives are scored by comparing growth inhibition zones on test and control plates; zones should be larger on the plate inoculated with strain FGSC2725 than on the plate inoculated with strain FGSC2721.

Two panels of compounds, one containing the fungicides and other pesticides having different mechanisms of action as set out in Table 1, and a second containing 117 antibiotics and antifungals listed in Table 2, are tested using the screen. The compounds are tested by disk diffusion assay at a rate of 20 μg/disk. Six active compounds are observed: gliotoxin, moxidectin, thiolutin, antibiotic F42248α, anisomycin and auriothin.

8

TABLE 1 - Standard Fungicide Panel

Compound	Target
amphotericin B	plasma membrane (polyene)
cerulenin	fatty acid biosynthesis
haloprogin	respiration
ketoconazole	ergosterol biosynthesis (lanosterol 14α-demethylase)
miconazole	ergosterol biosynthesis (lanosterol 14α-demethylase)
diniconazole	ergosterol biosynthesis (lanosterol 14α-demethylase)
econazole	ergosterol biosynthesis (lanosterol 14α-demethylase)
fenarimole	ergosterol biosynthesis (sterol Δ14 reductase)
tridemorph	ergosterol biosynthesis (sterol Δ14 reductase)
tolnaftate	ergosterol biosynthesis (squalene mono--oxygenase)
U18666A	ergosterol biosynthesis (squalene cyclase)
cycloheximide	protein biosynthesis
polyoxin D	chitin biosynthesis (cell wall)
nikkomycin	chitin biosynthesis (cell wall)
nocodazole	microtubule
benomyl	microtubule
maneb	multi-target
metalaxyl	rRNA biosynthesis
vinclozolin	lipid peroxidation
kanamycin	mitochondria

9

TABLE 1 - Continued - Standard Fungicide Panel

Compound	Target
tunicamycin	glycoprotein biosynthesis
carboxin	succinate dehydrogenase
cyanobutarate	microtubule (plant)
antimycin	respiration
5-fluoro-cytosine	nucleotide metabolism
glyphosate	herbicide (aromatic amino acid biosynthesis)
phosphinothricin	herbicide (glutamine biosynthesis)
aminotriazole	herbicide (histidine biosynthesis)
sulfometuron methyl	herbicide (branched chain amino acid biosynthesis)
pendimethalin	herbicide (microtubule)

TABLE 2 - Standard Antibiotic Panel

4-dedimethylamino-4-methyl-amino-anhydrotetracycline	Actinomycin crude
	Actithiazic acid/Mycobacidin
Alazopeptin	Amphomycin, Ca
Angustmycin	Anisomycin
Anthelmycin	Antibiotic A531
Antibiotic A4825	Antibiotic A7363
Antibiotic A8363	Antibiotic A9537
Antibiotic AC541, sulfate	Antibiotic AD97
Antibiotic AF283 α	Antibiotic AM31 β & γ
Antibiotic AM374 #22	Antibiotic AN 272 α
Antibiotic AO341β HCl	Antibiotic BL580 α
Antibiotic BL580 ζ	Antibiotic BM123 α, SO_4

10

TABLE 2 - Continued - Standard Antibiotic Panel

Compound	Target
Antibiotic BM123 γ HCl	Antibiotic BM782 E
Antibiotic BO2964 complex	Antibiotic BO4088
Antibiotic C08078 α	Antbiotic C19004 α
Antibiotic E19020 α	Antibiotic E19085 α
Antibiotic F42248 α	Antibiotic RA6950 β-B
Antibiotic V214X	Antibiotic V214W
Antibiotic Z-1220A #3	Antibiotic F28249 α
Antiprotozoin	Ascotoxin
Aspartocin, Na salt	Aureothin
Aureofungin	Avilamycin
Avoparcin sulfate	Azalomycin F
Bacitracin	Blasticidin "S"
Bottromycin	Cabomycin
Chloramphenical	Citrinin
Clavacin/Patulin	Declomycin HCl
Dermostatin	Destomycin A
Etamycin, Na salt	Flavofungin
Folimycin	Frenolicin (AC860 α)
Fusarinic acid	Geldamycin
Gibberellic acid	Gliotoxin
Griseofulvin, 5OH	Hamycin
Hygromycin A	Isoquinocycline HCl(AA575)
Lemonomycin	Leucomycin
Levomycin	Lincomycin HCl
Mocimycin	Monazomycin
Monicamycin	Moxidectin
Mycolutein	Mycophenolic acid
Mycorhodin	Naramycin B

TABLE 2 - Continued - Standard Antibi tic Panel

Compound	Target
Neohumidin	Neomycin SO_4
Netropsin, HCl	Neutramcin
Nonactin (AE409 γ)	Nosiheptide
Nucleocidin	Nybomycin
Nystatin	Paromomycin, sulfate
Pentamycin	Phenazine α-COOH
Picromycin	Piramicin/Tennectin
Polymyxin-B-sulfate	Protomycin/Streptimidone
Puromycin Aminonucleoside	Puromycin HCl
Pyrenophorin	Ramulosin
Relomucin, LL-AM684 β	Ristocetin
Rugulosin	Sparsomycin
Streptogramin/Vertimycin	Streptomycin SO_4
Sulfocidin	Tennecetin
Tetrahydro spiramycin base	Thioaurin
Thiolutin	Trichomycin
Tubercidin	Tylosin, tartrate
Usnic acid	Valinomycin/Miticide
Vancomycin HCl	Viomycin, sulfate

Using a qualitative scoring system based on zone size differences observed in the assay, 28 weak, 10 moderate and 4 strong actives are obtained in a screening of about 7000 synthetic compounds using the method.

Example 2

This example describes the cloning and sequencing of the *Saccharomyces cerevisiae* gene encoding sterol Δ14 reductase, and the preparation of a strain transformed with a plasmid containing the gene for use in the secondary screen described in the next example. The gene is isolated and cloned by selecting strains carrying sequences on a 2μ based vector for resistance to the morpholine fungicide, fenpropimorph, to obtain a plasmid which is shown to carry the structural gene based upon the phenotype of gene disruption strains.

Isolation and characterization of morpholine resistance plasmids. Morpholine and structurally related piperidine fungicides reportedly inhibit sterol Δ14 reductase and sterol Δ8 - Δ7 isomerase (Baloch, R. and Mercer, I., *Phytochemistry 26*: 663-668 (1987)). The growth of *S. cerevisiae* strain Y294, genotype MATα, leu2-3,112, ura3--52, his3Δ, trpl, Gal[+] (Brugge, J.S., *et al., Mol. Cell. Biol. 7*:2180-2187 (1987)), in SD medium supplemented with leucine, tryptophan, uracil and histidine is inhibited by 20 μg/ml of the morpholine fungicide fenpropimorph and 50 μg/ml of the morpholine fungicide tridemorph. Fenpropimorph is used for subsequent selection experiments because of its slightly greater potency.

When Y294 cells are plated onto 20 μg/ml of fenpropimorph in SD media supplemented with leucine, tryptophan, uracil and histidine, spontaneous mutants are recovered at the rate of ~1 per 2.5 x 10^6 plated

cells. When a library of *S. cerevisiae* sequences in the multicopy vector YEp13 (Nasmyth, K.A., and Tatchell, K., *Cell 19*: 753-764 (1980)) is introduced into strain Y294 and cells are plated on SD media supplemented with tryptophan, uracil, histidine and fenyropimorph, resistant colonies appeared at the rate of ~1 per 10^4, suggesting that resistance is produced by library plasmids in some of the colonies. Plasmids are cured from randomly selected resistant colonies by growing the cells in non-selective rich YEPD media and retesting for fenpropimorph resistance. In 13 strains, the plasmid-cured derivative shows sensitivity to 20 μg/ml fenpropimorph while the original plasmid carrying strain retested as fenpropimorph-resistant.

DNA is isolated from these 13 strains and plasmid DNA is recovered by *E. coli* transformation. Five different types of plasmid DNA are identified following an examination of restriction enzyme digestion patterns using standard methods (Figure 1). Seven strains carry one plasmid type, pML99, which has an insert of approximately 5.5 kb. Two additional strains carry a second plasmid type, pML-100, which has an insert of approximately 5.6 kb. A third plasmid type, pML101, is found in two strains and carries an insert of approximately 5.5 kb. Two additional plasmid types are each recovered from a single strain and named pML102 (~7.5 kb insert) and pML103 (~5.1 kb insert). One representative plasmid of each type is selected and subjected to extensive restriction enzyme analysis, which indicates that the insert from plasmid pML101 is contained within the insert from pML102 so that a total of four unique sequences are recovered in this selection. Restriction enzyme digestion maps of the four different insert sequences are shown in Figure 1.

A panel of fungicides representing a variety of chemical structures and mechanisms of action listed in Table 1 is tested by disk diffusion assay against strains carrying each of these plasmids in a YEp13 vector control. All five strains show similar levels of sensitivity to all of the tested compounds with the exception of the morpholines, fenpropimorph and tridemorph, and azasterol. These compounds are less active on the strains carrying the four plasmids recovered by selection for fenpropimorph resistance. Consistent with agar dilution sensitivity results, fenpropimorph is more active by disk diffusion than tridemorph. These results suggest that the cloned sequences encode functions specific to the activity of morpholines and related compounds and do not carry genes which produce general fungicide resistance, e.g., by altering cell permeability.

The library employed for the selection is prepared using DNA isolated from strain AB320 (genotype HO, ade2-1, lys2-1, trp5-2, leu2-1, can1-100, ura3-1 and/or ura1-1, met4-1, Nasmyth and Tatchell, cited above). When tested, strain AB320 is found to be slightly more sensitive to fenpropimorph than strain Y294, suggesting that the cloned sequences are likely to be producing resistance as the result of gene dosage effects.

Morpholine resistance in strains transformed with multi-copy ERG2 (sterol Δ8 - Δ7 isomerase) plasmids. One gene that would be expected to produce morpholine resistance at high copy is ERG2, which encodes a reported morpholine target, Δ8 - Δ7 isomerase. This gene was recently cloned by the complementation of a polyene resistance mutation (Ashman, cited above). The published ERG2 restriction map is different from the restriction maps of the four sequences recovered by morpholine resistance selection. Since it is possible that the ERG2 sequence is missed in the morpholine resistance screen, this gene is introduced into *S. cerevisiae* strain Y294 on the 2μ based plasmid, pML104, constructed by subcloning the ERG2 gene on a 2.1 kb *Hind*III fragment from plasmid PIU406 (Ashman, *et al.*, cited above) into the *Hind*III site of plasmid YEp351. This strain shows no increase in fenpropimorph resistance relative to YEp351-transformed control strain. Plasmid pML104 does, however, produce nystatin sensitivity when introduced into the erg2 mutant strain WAO (Ashman, *et al.*, cited above), demonstrating that plasmid pML104 carries a functional ERG2 gene. Sterol Δ8 - Δ7 isomerase may not over-express when present on a 2μ based, multi-copy plasmid, or the enzyme may not be a morpholine target in *S. cerevisiae*.

Characterization of fenpropimorph resistance plasmid pML100. The four fenpropimorph resistance plasmids pML99, pML100, pML101, and pML103 are transformed into three ergosterol pathway mutant strains, erg2 (denoted WAO, genotype MATa, his7-2, leu2-3,112, ura3-52, erg2-3, Ashman, *et al.*, cited above); erg3 (denoted XML39-1d, genotype MATa, leu2-3,112, erg3-2); and erg6 (denoted XML40-1c, genotype MATα, leu2-3,112, gal2, erg6-5). Morpholine sensitivity is determined by disk diffusion assay on appropriately supplemented SD medium using tridemorph and fenpropimorph. A zone size difference of greater than 3 mm performed in duplicate is recorded as resistance. The ergosterol pathway mutant strains vary in absolute level of morpholine sensitivity, and all resistance and sensitivity determinations are reported relative to vector (YEp-13)-transformed control strains. The results are tabulated in Table 3. Only plasmid pML100 transformants are consistently fenpropimorph-resistant in all genetic backgrounds, but the other plasmics are useful in screening methods.

13

TABLE 3

Plasmid Phenotype in Ergosterol Pathway Mutant Strains			
Strain	Ergosterol Genotype	Plasmid	Morpholine Resistance
Y294	ERG +	YEp13	-
Y294	ERG +	pML99	+
Y294	ERG +	pML100	+
Y294	ERG +	pML101	+
Y294	ERG +	pML103	+
WAO	erg2	YEp13	-
WAO	erg2	pML99	-
WAO	erg2	pML100	+
WAO	erg2	pML101	-
WAO	erg2	pML103	-
XML39-1d	erg3	YEp13	-
XML39-1d	erg3	pML99	+
XML39-1d	erg3	pML100	+
XML39-1d	erg3	pML101	-
XML39-1d	erg3	pML103	+ /-*
XML40-1c	erg6	YEp13	-
XML40-1c	erg6	pML99	+
XML40-1c	erg6	pML100	+
XML40-1c	erg6	pML101	-
XML40-1c	erg6	pML103	+ /-*

* - Resistance was observed with fenpropimorph but not tridemorph.

Resistance is also seen with other morpholine anti-fungals (tridemorph and fenpropidin) and azasterol, all of which are reported to be inhibitors of sterol Δ14 reductase. However, no increase is seen to a variety of other fungicides which are not sterol Δ14 reductase inhibitors. Since resistance occurs only to sterol Δ14 reductase inhibitors and is seen for such inhibitors from two different chemical classes, it is likely that pML100 encodes a function specific to sterol Δ14 reductase activity.

Subclones of the pML100 insert are prepared in the yeast shuttle vector YEp352, transformed into yeast strain Y294, and tested for fenpropimorph resistance. As shown in Figure 2, the fenpropimorph resistance region is limited to a 2.5 kb SphI/XbaI fragment located near one side of the insert/vector border.

Plasmid pML106, which contains this fragment in vector YEp352, is cleaved with BglII, which cuts once at a site near the middle of the SphI/XbaI fragment. A 3.0 kb BglII fragment containing the S. cerevisiae LEU2 gene is isolated from plasmid YEp13 and ligated into this BglII cite, producing plasmid pML108. The disrupted 5.5 kb SphI/XbaI fragment containing the LEU2 gene is isolated from plasmid pML108 and used to transform S. cerevisiae strain YPH501 to leucine prototrophy. Transformants in which the 5.5 kb SphI/XbaI fragment replaced the 2.5 kb SphI/XbaI fragment in one chromosomal homologue are identified by Southern analysis.

Tetrads from one such transformant (strain YPH501-2-1) are dissected and the spores germinated under anaerobic conditions on YEPD medium supplemented with Tween® 80 (500 μg/ml) and ergosterol (20 μg/ml). Strain YPH501-2-1 shows low (approximately 50%) spore viability, and no tetrads are recovered. This is found to be a property of strain YPH501 which showed a similar low level of spore viability when spores from the host strain are germinated anaerobically. By random spore analysis, 15 of 32 segregants are both Leu+ and obligate anaerobes, suggesting that the disruption has produced a genetic lesion in sterol biosynthesis. (The remaining 17 segregants are Leu− and grow aerobically.)

One such obligate anaerobe segregant, denoted YPH501-2-1-3C, is analyzed for sterol content. The strain is grown anaerobically on YEPD medium containing ergosterol (5 μg/ml) to facilitate sterol uptake. After one day, the cells are harvested, washed in saline, resuspended in YEPD medium with no added sterol and grown for an additional 2 days to deplete cellular sterol. After 3 days, sterols are extracted from stationary phase yeast cells into n-heptane and analyzed by ultraviolet (UV) between 200 and 300 nm, gas chromatography (GC) and gas chromatography-mass spectrometry (GC-MS). GC-MC analyses are performed on a Hewlett Packard (HP) 5980 instrument using a 30 meter x 0.25 mm HP-5 column with a 25 micron film thickness. The column temperature is programmed from 280°C to 300°C with the initial

14

temperature maintained for 2 minutes and increased at 3°C/minute. The final temperature is held for 6 minutes. The mass spectrometer is operated in the electron impact ionization mode at 70 eV. High pressure liquid chromatography (HPLC) analyses are performed using a reverse phase column (2.1 x 100 mm) packed with 5 micron spherical C18 bonded silica. Sterol samples are dissolved in a methanol:ethyl acetate (1:1) mixture and eluted from HPLC with 95% acetonitrile in water at 1 ml/minute. The detection wavelength is 270 nm.

UV analysis demonstrates a 250 nm broad peak indicative of a sterol containing a conjugated double bond system involving C-8(9) and C-14(15). GC analyses indicate a-major peak with the relative retention time of 1.30 consistent with ignosterol (ergosta-8,14-dien-3β-ol, molecular weight 398), the sterol Δ14 reductase substrate. GC-MS analysis confirms that the major sterol accumulating in this disrupted strain is ignosterol. Small amounts of lanosterol, approximately 5%, are also observed, consistent with a block in the sterol pathway downstream of lanosterol and affecting the reduction of the C-14 double bond. The accumulation of ignosterol indicates a genetic lesion in sterol Δ14 reductase activity.

DNA sequence analysis of plasmid pML100. The DNA sequence of the 2.5 kb SphI/XbaI fragment of plasmid pML100 is set out in the Sequence Listing section hereinafter as SEQ ID NO 1 and more particularly described in copending U.S. Application Number   filed concurrently with this application and incorporated in its entirety by reference. An open reading frame of 1314 base pairs is identified starting at an ATG codon at position 419 within the sequence. No other open reading frame of significant size is present within this fragment. Upstream of this ATG codon is an AT-rich sequence (66%), typical of many functionally expressed S. cerevisiae genes. This open reading frame encodes a 438 amino acid, 50.5 kilodalton basic (pI = 9.2), presumptive integral membrane protein which, based upon hydropathy analysis using a computer program that progressively evaluates the hydrophilicity and hydrophobicity of a protein along its amino acid sequence (Kyte, J., and Doolittle, R.F., J. Mol. Biol. 157: 105-132 (1982)), contains 8 or 9 putative transmembrane domains.

Other investigators report that selection for fenpropidin or fenpropimorph resistance in other S. cerevisiae strains produced plasmids exhibiting properties similar to pML100 (Lorenz and Parks, and Marcireau, C., et al., cited above).

Example 3

Compounds found to be actives in the primary screen of Example 1 are assayed using transformed strain Y294-(pML100) of Example 2 in a secondary screen.

Synthetic Dropout Media is first prepared by combining

Dropout Agar Base (DOBA, Bio-101)	44 g
CSM-LEU (Bio-101)	0.8 g
Distilled Water	1000 ml

and autoclaving 15 minutes at 20 pounds pressure.

Overnight cultures of Y294(pML100) and Y294(YEp13) are grown overnight in liquid synthetic dropout media (without agar) shaken at 30°C. The culture is grown to an OD$_{600}$ of ~2.5. One part of culture inoculum is added to 100 parts test media.

Test medium is prepared by combining 1 part Y294 (pML100) or Y294(YEp13) into warm synthetic dropout media. Pour plates for each culture, prepare test samples in duplicate and place each test sample on a Y294(pML100) plate and a Y294(YEp13) plate. A 1/4" disc containing 100 μg of fenpropimorph is used as a positive control. The plates are incubated at 30°C for two days and then examined to compare activity on the two strains. Actives produce a smaller zone on the Y294(pML100) plate than on the Y294(YEp13) plate.

Morpholines are detected in this assay at 12.5 μg/-disk for fenpropimorph and fenpropidin and 50 μg/disk for tridimorph. As a result, actives are generally concentrated 2500-fold prior to testing in the secondary screen. The same panel of fungicides set out in Table 1 and antibiotics set out in Table 2 (Example 1) are tested in the secondary screen. All of the actives from the primary screen with undesired mechanisms of action are inactive in the secondary assay. All of the active compounds from the panel of 7000 compounds tested in the primary screen of Example 1 were tested, and only one is active in the secondary screen. Thus, the two screens, when carried out together, are highly sensitive and specific for the detection of sterol Δ14 reductase inhibitors.

15

The above description is for the purpose of teaching the person of ordinary skill in the art how to practice the present invention, and it is not intended to detail all those obvious modifications and variations of it which will become apparent to the skilled worker upon reading the description. It is intended, however, that all such obvious modifications and variations be included within the scope of the present invention, which is defined by the following claims. The claims are intended to cover the claimed components and steps in any sequence which is effective to meet the objectives there intended, unless the context specifically indicates the contrary.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

     (i) APPLICANT: American Cyanamid Company

    (ii) TITLE OF INVENTION: Sterol Δ14 Reductase Screen

   (iii) NUMBER OF SEQUENCES: 2

    (iv) CORRESPONDENCE ADDRESS:
        (A) ADDRESSEE: American Cyanamid Company
        (B) STREET: One Cyanamid Plaza
        (C) CITY: Wayne
        (D) STATE: New Jersey
        (E) COUNTRY: United States
        (F) ZIP: 07470

     (v) COMPUTER READABLE FORM:
        (A) MEDIUM TYPE: Floppy disk
        (B) COMPUTER: IBM PC compatible
        (C) OPERATING SYSTEM: PC-DOS/MS-DOS
        (D) SOFTWARE: PatentIn Release #1.0, Version #1.25

    (vi) CURRENT APPLICATION DATA:
        (A) APPLICATION NUMBER: EP 94111839.0
        (B) FILING DATE: 29-JUL-1994
        (C) CLASSIFICATION:

   (viii) ATTORNEY/AGENT INFORMATION:
        (A) NAME: Wachtershauser, Gunter
        (C) REFERENCE/DOCKET NUMBER: 32,141\EA-9328

    (ix) TELECOMMUNICATION INFORMATION:
        (A) TELEPHONE: 201-831-3247
        (B) TELEFAX: 201-831-3250

(2) INFORMATION FOR SEQ ID NO:1:

     (i) SEQUENCE CHARACTERISTICS:
        (A) LENGTH: 2528 base pairs
        (B) TYPE: nucleic acid
        (C) STRANDEDNESS: double
        (D) TOPOLOGY: linear

    (ii) MOLECULE TYPE: DNA (genomic)

    (vi) ORIGINAL SOURCE:
        (A) ORGANISM: Saccharomyces cerevisiae

    (ix) FEATURE:
        (A) NAME/KEY: CDS
        (B) LOCATION: 419..1732

    (xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```
ATATATATAT ACCTCTTGCC AGCAACAGGC CAGTTATAAG TTAAAATTAA TATGTGACGC        60

ACTTCTGAAA CAGTATTGAA ACAGTATTGA AACATATGTA TTACCCGGAC TCTGCATGCT       120

CTGTCGTTCA TTTTATTTTC ACCTAAACGA AAATCCCGTG AAAAAAATTT ATATCGCCTT       180

TCGCTCTTTT GTATGTAGGC ATCATCGGAA ATTTGCATTG TGTGAAGGTT GTGCATATAA       240

AGGGTTTTGC ATAACGGACG TTTTTCACGT ACTCCGTCTG AGCATCAAGT GAGGCTTGAG       300
```

```
TTTACGTTTG TTTTTAATAA TCAGTTTTCA TTCTACTATT TTCTTGCGCA ATTGCTTATC        360

AGATAGACCT TGTAAACAGC ATAGGAGTAA AGACAAATTC GGTGTAGAGA ATAAAAGG          418
```

```
5    ATG GTA TCA GCT TTG AAT CCC AGA ACT ACA GAG TTT GAA TTT GGT GGG       466
     Met Val Ser Ala Leu Asn Pro Arg Thr Thr Glu Phe Glu Phe Gly Gly
      1               5               10                  15

     CTG ATT GGT GCC TTA GGC ATC AGC ATA GGG CTG CCT GTT TTC ACT ATC       514
     Leu Ile Gly Ala Leu Gly Ile Ser Ile Gly Leu Pro Val Phe Thr Ile
                      20              25                  30
10
     ATC TTG AAT CAA ATG ATA AGG CCC GAT TAT TTT ATT AAG GGA TTT TTC       562
     Ile Leu Asn Gln Met Ile Arg Pro Asp Tyr Phe Ile Lys Gly Phe Phe
                  35              40                  45

     CAG AAT TTC GAT ATA GTT GAG CTT TGG AAC GGT ATC AAG CCA TTG CGC       610
     Gln Asn Phe Asp Ile Val Glu Leu Trp Asn Gly Ile Lys Pro Leu Arg
15                50              55                  60

     TAC TAT CTG GGC AAT CGT GAA TTA TGG ACT GTC TAT TGC CTG TGG TAT       658
     Tyr Tyr Leu Gly Asn Arg Glu Leu Trp Thr Val Tyr Cys Leu Trp Tyr
     65                  70              75                  80

20   GGA ATA CTG GCA GTT TTG GAC GTC ATT TTA CCG GGC AGA GTC ATG AAG       706
     Gly Ile Leu Ala Val Leu Asp Val Ile Leu Pro Gly Arg Val Met Lys
                      85              90                  95

     GGT GTT CAG TTA AGG GAT GGT TCG AAG CTT TCG TAT AAG ATC AAT GGA       754
     Gly Val Gln Leu Arg Asp Gly Ser Lys Leu Ser Tyr Lys Ile Asn Gly
                     100             105                 110
25
     ATT GCC ATG TCT ACA ACT TTG GTC TTA GTT TTG GCT ATC AGA TGG AAA       802
     Ile Ala Met Ser Thr Thr Leu Val Leu Val Leu Ala Ile Arg Trp Lys
                  115             120                 125

     TTG ACT GAT GGA CAA TTG CCT GAA TTG CAA TAT CTG TAT GAA AAT CAC       850
     Leu Thr Asp Gly Gln Leu Pro Glu Leu Gln Tyr Leu Tyr Glu Asn His
                  130             135                 140
30
     GTT AGT TTA TGC ATA ATA TCT ATT TTG TTT TCG TTC TTT TTG GCG ACG       898
     Val Ser Leu Cys Ile Ile Ser Ile Leu Phe Ser Phe Phe Leu Ala Thr
     145                 150             155                 160

     TAC TGC TAT GTT GCC AGC TTC ATA CCA TTG ATC TTC AAG AAA AAT GGT       946
     Tyr Cys Tyr Val Ala Ser Phe Ile Pro Leu Ile Phe Lys Lys Asn Gly
35                    165             170                 175

     AAT GGC AAA AGG GAA AAG ATC TTA GCA CTA GGT GGA AAT TCA GGA AAC       994
     Asn Gly Lys Arg Glu Lys Ile Leu Ala Leu Gly Gly Asn Ser Gly Asn
                     180             185                 190

40   ATC ATT TAC GAT TGG TTT ATT GGT AGA GAA CTG AAC CCT CGT CTC GGC      1042
     Ile Ile Tyr Asp Trp Phe Ile Gly Arg Glu Leu Asn Pro Arg Leu Gly
                     195             200                 205

     CCA TTA GAT ATC AAG ATG TTT TCA GAG TTG AGA CCC GGC ATG TTG TTA      1090
     Pro Leu Asp Ile Lys Met Phe Ser Glu Leu Arg Pro Gly Met Leu Leu
                  210             215                 220
45
     TGG TTA CTG ATC AAT CTT TCC TGT CTG CAT CAC CAT TAC CTG AAG ACT      1138
     Trp Leu Leu Ile Asn Leu Ser Cys Leu His His His Tyr Leu Lys Thr
     225                 230             235                 240

     GGT AAA ATC AAC GAT GCA TTG GTC TTG GTT AAT TTC TCG CAA GGA TTT      1186
     Gly Lys Ile Asn Asp Ala Leu Val Leu Val Asn Phe Ser Gln Gly Phe
50                   245             250                 255

     TAC ATT TTC GAT GGA GTA CTA AAC GAG GAA GGT GTA TTA ACC ATG ATG      1234
```

```
          Tyr Ile Phe Asp Gly Val Leu Asn Glu Glu Gly Val Leu Thr Met Met
                      260                 265                 270

      GAT ATC ACT ACA GAT GGG TTT GGT TTC ATG CTA GCG TTT GGT GAC TTA        1282
5     Asp Ile Thr Thr Asp Gly Phe Gly Phe Met Leu Ala Phe Gly Asp Leu
              275             280                 285

      AGT TTA GTT CCA TTC ACC TAC TCA TTA CAA GCG CGT TAC TTG AGT GTT        1330
      Ser Leu Val Pro Phe Thr Tyr Ser Leu Gln Ala Arg Tyr Leu Ser Val
          290             295                 300

10    TCC CCT GTG GAA TTG GGA TGG GTG AAA GTT GTC GGT ATA TTA GCC ATA        1378
      Ser Pro Val Glu Leu Gly Trp Val Lys Val Val Gly Ile Leu Ala Ile
      305                 310                 315                 320

      ATG TTT TTG GGT TTC CAC ATC TTC CAC TCG GCA AAT AAG CAA AAA TCT        1426
      Met Phe Leu Gly Phe His Ile Phe His Ser Ala Asn Lys Gln Lys Ser
                      325             330                 335
15
      GAG TTT AGA CAA GGT AAA TTA GAA AAT CTA AAA AGT ATT CAG ACA AAG        1474
      Glu Phe Arg Gln Gly Lys Leu Glu Asn Leu Lys Ser Ile Gln Thr Lys
                  340             345                 350

      CGT GGT ACA AAG TTA TTA TGT GAC GGG TGG TGG GCT AAA TCA CAG CAT        1522
20    Arg Gly Thr Lys Leu Leu Cys Asp Gly Trp Trp Ala Lys Ser Gln His
                  355             360                 365

      ATC AAT TAC TTT GGC GAT TGG CTG ATT TCA TTA AGT TGG TGT TTG GCC        1570
      Ile Asn Tyr Phe Gly Asp Trp Leu Ile Ser Leu Ser Trp Cys Leu Ala
              370             375             380

      ACC TGG TTC CAA ACT CCC TTG ACA TAT TAC TAC TCG TTG TAC TTC GCC        1618
25    Thr Trp Phe Gln Thr Pro Leu Thr Tyr Tyr Tyr Ser Leu Tyr Phe Ala
      385             390                 395             400

      ACG TTG TTA TTA CAC CGT CAA CAA CGT GAT GAG CAC AAG TGC CGC CTG        1666
      Thr Leu Leu Leu His Arg Gln Gln Arg Asp Glu His Lys Cys Arg Leu
                  405             410                 415
30
      AAA TAT GGC GAA AAT TGG GAA GAA TAC GAA AGA AAA GTT CCT TAC AAG        1714
      Lys Tyr Gly Glu Asn Trp Glu Glu Tyr Glu Arg Lys Val Pro Tyr Lys
                  420             425                 430

      ATC ATT CCA TAT GTT TAT TAAGTTTTTC TACCACTGCT ATTTTCTTCA              1762
      Ile Ile Pro Tyr Val Tyr
                  435
35
      TTATCTATGT ATGTGTGTAT ACATGTTATG TATTGGGTGA GTATGAGGAA GAAGAAGAAT     1822

      AACAATTGAA AACGCTGGAA AAATTAAAAG GGGTGGCGGT CTATCTATGC AACGCTCCCC     1882

      TTTTCGTTAC ATGAACACAT CAAACTTGTA TATCCTTTGA GTGTTCTTTA ATCAAGTCAT     1942
40
      CTTGGTATTT TAGTAGCGTT CCACTACTT TAGGGACAAA TTCAGACCTA ACCAATCCAT      2002

      CAAAAGCATC AAACCCTTGC GACAAAATCG GAATATCAGA CTCGCCATGC ATAAACTCTG     2062

      GAATTTCTAG TTTCCCGTCC GCAAGTATGC CGTCATCATC CTCGTCGTCC TTATTAGTAT     2122

45    CCAAATTTGT CACTTTGACG TTCATCGACA ACTGTAAGTC AAAGTAGCAA ATCGCCTTGC     2182

      CCTTCCTTTG AGATACGTTG GAGTCACCGG TGATGCTACT CACCTGGGTT AACTCAATTT     2242

      TGCTCTTCCC ATCAGAGGAA ACAGTGGACA AACTCGTTAA TTTACCGTTC AAGTAGTCCT     2302

      TAGACCAAGG TAAGGTGTTT TTATCCACCC AATGCCAGTT ATTTGGATTC AAGACAACCA     2362
50
      TATTTTATCG TAAATGTGTT GTAACTTTCC GATCGTTTCA AACTTTAGTA GTAGTTTGAT     2422
```

55

```
GATTTTGTCC AAAAAGTATT TGCTTAAATT TCAGCTTTTT TCTTCTTCAT ATGTATTTCT      2482

TTTTTTCCTC GCTTTCTCTG CCCACTTTTT TCTTCTGTCT TCTAGA                     2528
```

(2) INFORMATION FOR SEQ ID NO:2:

  (i) SEQUENCE CHARACTERISTICS:
    (A) LENGTH: 438 amino acids
    (B) TYPE: amino acid
    (D) TOPOLOGY: linear

  (ii) MOLECULE TYPE: protein

  (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2:

```
Met Val Ser Ala Leu Asn Pro Arg Thr Thr Glu Phe Glu Phe Gly Gly
 1           5               10              15

Leu Ile Gly Ala Leu Gly Ile Ser Ile Gly Leu Pro Val Phe Thr Ile
            20              25              30

Ile Leu Asn Gln Met Ile Arg Pro Asp Tyr Phe Ile Lys Gly Phe Phe
            35              40              45

Gln Asn Phe Asp Ile Val Glu Leu Trp Asn Gly Ile Lys Pro Leu Arg
        50              55              60

Tyr Tyr Leu Gly Asn Arg Glu Leu Trp Thr Val Tyr Cys Leu Trp Tyr
65              70              75              80

Gly Ile Leu Ala Val Leu Asp Val Ile Leu Pro Gly Arg Val Met Lys
            85              90              95

Gly Val Gln Leu Arg Asp Gly Ser Lys Leu Ser Tyr Lys Ile Asn Gly
            100             105             110

Ile Ala Met Ser Thr Thr Leu Val Leu Val Leu Ala Ile Arg Trp Lys
            115             120             125

Leu Thr Asp Gly Gln Leu Pro Glu Leu Gln Tyr Leu Tyr Glu Asn His
        130             135             140

Val Ser Leu Cys Ile Ile Ser Ile Leu Phe Ser Phe Phe Leu Ala Thr
145             150             155             160

Tyr Cys Tyr Val Ala Ser Phe Ile Pro Leu Ile Phe Lys Lys Asn Gly
            165             170             175

Asn Gly Lys Arg Glu Lys Ile Leu Ala Leu Gly Gly Asn Ser Gly Asn
            180             185             190

Ile Ile Tyr Asp Trp Phe Ile Gly Arg Glu Leu Asn Pro Arg Leu Gly
            195             200             205

Pro Leu Asp Ile Lys Met Phe Ser Glu Leu Arg Pro Gly Met Leu Leu
        210             215             220

Trp Leu Leu Ile Asn Leu Ser Cys Leu His His His Tyr Leu Lys Thr
225             230             235             240

Gly Lys Ile Asn Asp Ala Leu Val Leu Val Asn Phe Ser Gln Gly Phe
            245             250             255

Tyr Ile Phe Asp Gly Val Leu Asn Glu Glu Gly Val Leu Thr Met Met
            260             265             270

Asp Ile Thr Thr Asp Gly Phe Gly Phe Met Leu Ala Phe Gly Asp Leu
            275             280             285
```

```
        Ser Leu Val Pro Phe Thr Tyr Ser Leu Gln Ala Arg Tyr Leu Ser Val
            290                 295                 300

        Ser Pro Val Glu Leu Gly Trp Val Lys Val Val Gly Ile Leu Ala Ile
        305                 310                 315                 320

        Met Phe Leu Gly Phe His Ile Phe His Ser Ala Asn Lys Gln Lys Ser
                        325                 330                 335

        Glu Phe Arg Gln Gly Lys Leu Glu Asn Leu Lys Ser Ile Gln Thr Lys
                    340                 345                 350

        Arg Gly Thr Lys Leu Leu Cys Asp Gly Trp Trp Ala Lys Ser Gln His
                355                 360                 365

        Ile Asn Tyr Phe Gly Asp Trp Leu Ile Ser Leu Ser Trp Cys Leu Ala
            370                 375                 380

        Thr Trp Phe Gln Thr Pro Leu Thr Tyr Tyr Tyr Ser Leu Tyr Phe Ala
        385                 390                 395                 400

        Thr Leu Leu Leu His Arg Gln Gln Arg Asp Glu His Lys Cys Arg Leu
                        405                 410                 415

        Lys Tyr Gly Glu Asn Trp Glu Glu Tyr Glu Arg Lys Val Pro Tyr Lys
                420                 425                 430

        Ile Ile Pro Tyr Val Tyr
                435
```

BIBLIOGRAPHY

Ashman, W.H., *et al.*, Lipids *26*: 628-632 (1991).

Baloch, R. and Mercer, I., *Phytochemistry 26*: 663-668 (1987).

Brugge, J.S., *et al.*, *Mol. Cell. Biol. 7*:2180-2187 (1987).

Ellis, S.W., *et al.*, *J. Gen. Micro. 137*: 267-272 (1992).

Grindle, M., and Farrow, R., *Mol. Gen. Genet. 165*: 305-308 (1978).

Kyte, J., and Doolittle, R.F., *J. Mol. Biol. 157*: 105-132 (1982).

Lorenz, T., and Parks, L.W., *DNA and Cell Biol. 11*: 685-692 (1992).

Marcireau, C., *et al.*, *Curr. Genet. 22*: 267-272 (1992).

Mercer, E.I., *Biochem. Soc. Trans. 19*: 788-308 (1991).

Nasmyth, K.A., and Tatchell, K., *Cell 19*: 753-764 (1980).

Paltauf, F., *et al.*, in Jones, E.W., *et al.*, eds., *The Molecular and Cellular Biology of the Yeast Saccharomyces, Gene Expression*, Cold Spring Harbor Laboratory Press, 1992, pages 415, 418-420, 424-428 and 434-437.

Claims

1. A method for screening for the presence or absence of sterol Δ14 reductase inhibition by a test sample, said method comprising:

   (a) adding the test sample to a culture of a *Neurospora crassa* strain having an erg-3 mutation;

   (b) adding the test sample to a second culture of a *Neurospora crassa* strain having an erg-1 mutation;

   (c) incubating the cultures for such time under such conditions sufficient to observe fungal cell growth in corresponding cultures containing no test sample;

   (d) comparing the extent of growth inhibition in the culture containing the erg-3 mutation with the extent of growth inhibition in the culture containing the erg-1 mutant; and

   (e) determining the presence of sterol biosynthesis inhibition by observation that growth inhibition in the erg-3 culture exceeds growth inhibition in the erg-1 culture.

2. A method according to claim 1 further comprising, as a control, adding a known inhibitor of sterol Δ14 reductase to both *N. crassa strains* prior to incubation.

3. A method according to claim 1 wherein said *N. crassa* strain having an erg-1 mutation is strain FGSC2721 and said strain having an erg-3 mutation is strain FGSC2725 obtained from the Fungal Genetics Stock Center.

4. A method for screening for the presence or absence of sterol Δ14 reductase inhibition by a test sample, said method comprising:

(a) adding the test sample to a culture of a *Saccharomyces cerevisiae* strain into which has been introduced a gene encoding sterol Δ14 reductase;

(b) adding the test sample to a culture of a corresponding *Saccharomyces cerevisiae* strain which does not have an introduced sterol Δ14 reductase gene;

(c) incubating the test sample in the cultures for such time under such conditions sufficient to observe yeast cell growth in corresponding cultures containing no test sample;

(d) comparing the extent of growth inhibition in the culture having the reductase gene with the extent of growth inhibition in the corresponding culture having no introduced gene; and

(e) determining the presence of sterol Δ14 reductase inhibition by observation that growth inhibition in the corresponding culture having no introduced reductase gene exceeds growth inhibition in the culture having the introduced reductase gene.

5. A method according to claim 4 further comprising, as a control, adding a known inhibitor of sterol Δ14 reductase to both yeast strains prior to incubation.

6. A method according to claim 1 or 5 wherein the known inhibitor of sterol Δ14 reductase is selected from the group consisting of fenpropimorph, fenpropidin, tridimorph, and azasterol.

7. A method according to claim 4 wherein the strain is Y294(pML100).

8. A method according to claim 7 wherein the culture of a corresponding *Saccharomyces cerevisiae* strain which does not have an introduced sterol Δ14 reductase gene is Y294(YEp13).

9. A method according to claim 1 or 4 wherein the cultures containing test samples are solidified cultures and test samples are added to the cultures on a disk or in a well.

10. A method for screening for the presence or absence of sterol Δ14 reductase inhibition by a test sample, which comprises:

(a) first screening the test sample in a primary screen comprising the steps of:

(i) adding the test sample to a culture of a *Neurospora crassa* strain having an erg-3 mutation;

(ii) adding the test sample to a second culture of a *Neurospora crassa* strain having an erg-1 mutation;

(iii) incubating the test samples in the cultures for such time under such conditions sufficient to observe fungal cell growth in corresponding cultures containing no test sample;

(iv) comparing the extent of growth inhibition in the culture containing the erg-3 mutation with the extent of growth inhibition in the culture containing the erg-1 mutant; and

(v) identifying a positive test sample by observing that growth inhibition in the erg-3 culture containing the test sample exceeds growth inhibition in the erg-1 culture containing the test sample; followed by

(b) screening said positive test sample in a secondary screen comprising the steps of:

(vi) adding a positive test sample from the primary screen to a culture of a *Saccharomyces cerevisiae* strain into which has been introduced at high copy a gene encoding sterol Δ14 reductase;

(vii) adding the positive test sample to a culture of a corresponding *Saccharomyces cerevisiae* strain which does not have an introduced sterol Δ14 reductase gene;

(viii) incubating the samples in the cultures for such time under such conditions sufficient to observe yeast cell growth in corresponding cultures containing no test sample;

(ix) comparing the extent of growth inhibition in the culture having the reductase gene with the extent of growth inhibition in the corresponding culture having no introduced gene; and

22

(x) determining the presence of sterol Δ14 reductase inhibition by observation that inhibition in the culture having no introduced reductase gene exceeds growth inhibition in the corresponding culture having the introduced reductase gene.

11. A method according to claim 10 further comprising, as a control, adding a known inhibitor of sterol Δ14 reductase to both *N. crassa* and both *S. cerevisiae* strains prior to incubation during the respective primary and secondary screens.

12. A method for screening for sterol Δ14 reductase inhibition according to claim 10 which comprises:
   (a) first screening the test sample in a primary screen comprising the steps of:
      (i) adding, on a disk or in a well, the test sample to a solidified culture of FGSC2725;
      (ii) adding, on a disk or in a well, the test sample to a solidified culture of FGSC2721;
      (iii) adding to both cultures, on a disk or in a well, tridemorph as a control;
      (iv) incubating the test samples and controls in the cultures for such time under such conditions sufficient to observe fungal cell growth in corresponding cultures containing no test sample and growth inhibition in the vicinity of the control disk or well;
      (v) comparing the extent of growth inhibition in the culture containing FGSC2725 with the extent of growth inhibition in the culture containing FGSC2721; and
      (vi) identifying a positive test sample by observation that growth inhibition in the FGSC2725 culture containing the test sample exceeds growth inhibition in the FGSC2721 culture; followed by
   (b) screening a positive test sample in a secondary screen comprising the steps of:
      (vii) adding, on a disk or in a well, a positive test sample from the primary screen to a solidified culture of *Saccharomyces cerevisiae* strain Y294(pML100);
      (viii) adding, on a disk or in a well, the positive test sample to a solidified culture of *Saccharomyces cerevisiae* strain Y294(YEp-13);
      (ix) adding to both cultures, on a disk or in a well, fenprophimorph as a control;
      (x) incubating the samples in the cultures for such time under such conditions sufficient to observe yeast cell growth in corresponding cultures containing no test sample and yeast cell growth inhibition in the vicinity of the control disk or well in culture Y294(YEp13) and Y294-(pML100);
      (xi) comparing the extent of growth inhibition in the culture having the reductase gene with the extent of growth inhibition in the culture having no introduced gene; and
      (xii) determining the presence of sterol Δ14 reductase inhibition by observation that growth inhibition in the Y294(YEp13) culture exceeds growth inhibition in the Y294(pML100) culture.

13. A plasmid obtained by a process which comprises recovering plasmids selected for resistance to a morpholine fungicide in *S. cerevisiae* strains carrying DNA sequences on a 2μ vector.

14. A method according to claim 4 wherein said *S. cerevisiae* strain into which has been introduced a sterol Δ14 reductase gene is a strain transformed with a plasmid selected from the group consisting of pML99, pML100, pML101 and pML103.

FIGURE 1

FIGURE 2

FIGURE 1

FIGURE 2

• Kirsch, Donald Richard
Princeton, New Jersey 07066 (US)
• Bard, Martin
Carmel, Indiana 46032 (US)

(74) Representative: Wächtershäuser, Günter, Prof. Dr.
Patentanwalt,
Tal 29
80331 München (DE)

(54) **Sterol delta-14 reductase screen**

(57) A binary assay identifies agents that inhibit sterol Δ14 reductase involved in ergosterol biosynthesis. In the primary screen, sterol Δ14 reductase inhibition by a test sample is assayed by adding the test sample to a culture of *Neurospora crassa* having an erg-3 mutation and also to a culture of a strain having an erg-1 mutation, comparing the extent of growth inhibition after incubation in the two cultures, and identifying as positives those samples that show growth inhibition in the erg-3 culture exceeding that in the erg-1 culture. In the secondary screen, samples that test positive in the primary screen are reassayed by adding the test sample to a culture of a *Saccharomyces cerevisiae* strain into which has been introduced multiple copies of a gene encoding sterol Δ14 reductase and also to a strain of *S. cerevisiae* that does not have the introduced gene; positive samples are identified after incubation by observation that growth inhibition in the culture having no introduced reductase gene exceeds growth inhibition in the culture having the introduced reductase gene. In preferred embodiments, a known inhibitor of sterol Δ14 reductase is employed in solidified media in both the primary and the secondary screens, resulting in an assay that is highly sensitive and specific for the detection of sterol Δ14 reductase inhibitors.

European Patent Office

EUROPEAN SEARCH REPORT

Application Number

EP 94 11 1839

DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
D,A	CURRENT GENETICS, vol. 22, no. 4, October 1992, BERLIN, pages 267-272, XP000196020 MARCIREAU ET AL.: "Construction and growth properties of a yeast strain defective in sterol 14-reductase" ---		C12Q1/18 C12Q1/26 C12N15/53
D,A	MOLECULAR & GENERAL GENETICS, vol. 165, 1978, BERLIN, pages 305-308, XP000196026 GRINDLE ET AL.: "Sterol content and enzyme defects of nystatin-resistant mutants of neurospora crassa" ---		
D,A	JOURNAL OF GENERAL MICROBIOLOGY, vol. 137, no. 11, November 1991, LONDON, pages 2627-2630, XP000196027 ELLIS ET AL.: "Identification of a sterol mutant of Neurospora crassa deficient in delta14,15-reductase activity" -----		
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C12Q

The present search report has been drawn up for all claims

Place of search	Date of completion of the search	Examiner
BERLIN	15 May 1996	Ceder, O

CATEGORY OF CITED DOCUMENTS

X : particularly relevant if taken alone
Y : particularly relevant if combined with another document of the same category
A : technological background
O : non-written disclosure
P : intermediate document

T : theory or principle underlying the invention
E : earlier patent document, but published on, or after the filing date
D : document cited in the application
L : document cited for other reasons

& : member of the same patent family, corresponding document

EPO FORM 1503 03.82 (P04C01)